Experts call for additions to strengthen act amending drug legislation

Several experts say the federal government’s attempt to strengthen the powers of the Food and Drug Act haven’t gone far enough. They applaud some of the provisions in Bill C-17, but say additional powers are needed to protect the public.

Several experts say the federal government’s attempt to strengthen the powers of the Food and Drug Act haven’t gone far enough.

They applaud some of the provisions in Bill C-17, but say additional powers are needed to protect the public.

They make their argument in a commentary published in this week’s issue of the Canadian Medical Association Journal.

The act, which was introduced in Parliament in early December, gives the federal health minister long-overdue powers to order the recall of a drug for safety reasons.

Currently Health Canada must negotiate recalls with drug manufacturers, which can result in a drug remaining on the market after it has been deemed to be dangerous. The researchers worry that the proposed amendments say recalls can be unilaterally ordered when evidence shows a drug is unsafe; they say the minister should be able to act when he or she has reasonable grounds to believe the drug could cause harm.

They also suggest the legislation should exempt the health minister from liability on drug suspensions and recalls, saying that without it the threat of being sued would be a strong disincentive to use the recall power.

The lead author of the commentary was Matthew Herder, who teaches health law in Dalhousie University’s faculty of medicine. He and his co-authors argue that the act should address the need for greater transparency in the data drug companies derive from the clinical trials they conduct.

The U.S. and Europe require that clinical trials are registered — a move Canada has not followed to date. Health Canada maintains a database of clinical trials, but stipulates it is not a registry and doesn’t contain comprehensive information about all clinical trials. The authors suggest the data from these trials should be available for scrutiny by researchers.

They also call for more transparency on the part of Health Canada, saying the regulator should make public the rationale for its decisions — and, in fact, should make all its decisions public. Currently Health Canada does not disclose when it has turned down a drug application, though its European counterpart does release negative opinions.

As the legislation currently stands — or is interpreted — too much information that the public needs is withheld on the grounds it is proprietary or is a trade secret, the commentary notes.

“These assertions overstate what the law actually requires and prevent important information about safety and effectiveness from being released,” the authors write. “Bill C-17 should explicitly state that the results of clinical trials, including de-identified patient level data, post-marketing studies and adverse drug reactions reported by drug manufacturers and health-care institutions are not proprietary and therefore should be publicly disclosed.”

Just Posted

Sport of axe throwing growing in Red Deer

True North Axe Throwing wants sport to be ‘Canadian version of darts’

Optimism remains for Red Deer hospital expansion

Red Deer’s incoming UCP MLAs both have been strong supporters of expansion

RDC cancels championship-winning golf program due to tight finances

Short season, small number of student golfers were also considerations

Fire investigators comb through industrial fire wreckage looking for answers

Industrial building in north Red Deer was completely gutted in Wednesday morning fire

WATCH: An ‘Eggstemely Fun Easter’ at Bower Place in Red Deer

Bower Place mall made sure Red Deer families were able to have… Continue reading

Notre Dame rector: “Computer glitch” possible fire culprit

PARIS — A “computer glitch” may have been behind the fast-spreading fire… Continue reading

Former journalist pleads guilty to robbing two banks in Medicine Hat

MEDICINE HAT, Alta. — A former journalist arrested almost two years ago… Continue reading

Austria fears for three top climbers missing in Banff National Park

BERLIN — Austrian Chancellor Sebastian Kurz said Friday his thoughts are with… Continue reading

As Vancouver fights over 4-20, Seattle’s Hempfest enjoys tolerance, some support

VANCOUVER — They both came from humble beginnings: small protests against marijuana… Continue reading

All eyes on the surging Greens as Prince Edward Island goes to the polls

After a brief provincial election campaign devoid of drama, voters on Prince… Continue reading

North Dakota company where 4 were slain seeks normalcy

MANDAN, N.D. — Camaraderie was so important for the “coffee club” at… Continue reading

Trump blasts ex-advisers who say he tried to stop Mueller

WASHINGTON — A day after celebrating the release of the Mueller report… Continue reading

Sanders claims she didn’t lie, despite Mueller finding

WASHINGTON — President Donald Trump’s spokeswoman Sarah Sanders pushed back Friday against… Continue reading

Most Read